This inventor holds 11 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Novartis Ag, Ciba-Geigy Corporation, Ciba Specialty Chemicals Corporation. Active years: 1995-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
5 out of 3,977 
4 out of 6,858 
1 out of 1,524 
Years Active: 1995-2014
Title: Guido Jordine: Innovator in Pharmaceutical Compounds
Introduction
Guido Jordine is a prominent inventor based in Freiburg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating autoimmune conditions. With a total of 11 patents to his name, Jordine's work has had a substantial impact on medical research and treatment options.
Latest Patents
Among his latest patents, Jordine has developed organic compounds that relate to salts, polymorphs, and hydrates of 2-Amino-2-[2-(4-C-alkyl-phenyl)ethyl]propane-1,3-diol. This invention focuses on the use of these compounds in the treatment or prevention of various autoimmune conditions. Additionally, he has worked on ceramide-analogous metabolites, specifically ceramide-analogues of FTY720. This invention includes pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their application in treating autoimmune conditions such as multiple sclerosis.
Career Highlights
Throughout his career, Jordine has been associated with notable companies in the pharmaceutical industry, including Novartis AG and Ciba-Geigy Corporation. His work in these organizations has allowed him to advance his research and contribute to significant medical advancements.
Collaborations
Jordine has collaborated with esteemed colleagues such as Jean-Marie Adam and Michael Mutz. These partnerships have fostered innovation and have been instrumental in the development of his patented inventions.
Conclusion
Guido Jordine's contributions to pharmaceutical innovations demonstrate his commitment to improving treatment options for autoimmune conditions. His extensive patent portfolio reflects his expertise and dedication to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile